New York, NY – June 20, 2011 – TONIX Pharmaceuticals, a specialty pharmaceutical company developing prescription medications for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, announced that Professor Harvey Moldofsky, M.D., has joined the Company’s Scientific Advisory Board. Dr. Moldofsky has devoted his career to the study of sleep physiology and biologic rhythm and is renowned for his contributions to understanding the role of non-restorative sleep in fibromyalgia syndrome.
"We are pleased to announce that Harvey Moldofsky is joining our scientific advisory board," said Seth Lederman, M.D., Chairman and President of TONIX. "Harvey was Principal Investigator of our Phase 2a study which demonstrated that bedtime administration of very low dose cyclobenzaprine (VLDC) reduced pain, fatigue and tenderness in patients suffering from fibromyalgia.”
Dr. Moldofsky stated, “I look forward to serving on the Scientific Advisory Board of TONIX, working with the other distinguished members of the Board, and helping the company develop the technology to help fibromyalgia patients.”
Harvey Moldofsky is the President and Medical Director of the Sleep Disorders Clinic of the Center for Sleep and Chronobiology, the Wilson Sleep Disorders Clinic and President of the Toronto Psychiatric Research Foundation. He is an honorary member of the University Health Network Department of Psychiatry and Professor Emeritus of the Faculty of Medicine and Member Emeritus, Institute of Medical Science, School of Graduate Studies at the University of Toronto.
Dr. Moldofsky has been the recipient of many local, national and international awards, including the regional award of the Royal College of Physicians and Surgeons of Canada for his contributions as a medical educator. In 1989, The Dr. Harvey Moldofsky Scholarship for Psychiatric/Neuroscience Research was formed in his honor. It is awarded annually to a medical student of the University of Toronto.
About TONIX Pharmaceuticals
TONIX Pharmaceuticals is developing new treatments for challenging disorders of the central nervous system. The Company’s most advanced program targets fibromyalgia syndrome based on bedtime treatment with very low dosage cyclobenzaprine. Cyclobenzaprine in higher doses is the active ingredient of U.S. FDA approved muscle relaxants. Based on this foundation, the Company is building a deep and diverse pipeline of high-value medications for other syndromes, disorders and diseases, including post-traumatic stress disorder. For more information, please visit www.tonixpharma.com.